Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.62 |
| ▸ | AKT1 | P31749 | 3/20 | 0.55 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156256 | 0.83 | PIK3CA (0.67) | PIK3CAAKT1MTORKDM4EMEN1 | |
| SCHEMBL10157305 | 0.82 | PIK3CA (0.57) | PIK3CAAKT1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL730195 | 0.82 | PIK3CA (0.84) | PIK3CAAKT1MTORPIK3CGPIK3CD | |
| SCHEMBL729714 | 0.82 | PIK3CA (0.62) | PIK3CAAKT1MTORCYP1A2CYP3A4 | |
| SCHEMBL729005 | 0.81 | PIK3CA (0.65) | PIK3CAAKT1MTORIRAK4PIK3CG | |
| SCHEMBL730306 | 0.81 | PIK3CA (0.64) | PIK3CAAKT1MTORPIK3CGPIK3CD | |
| SCHEMBL730188 | 0.80 | PIK3CA (0.87) | PIK3CAAKT1MTORPIK3CGPIK3CD | |
| SCHEMBL731482 | 0.80 | PIK3CA (0.67) | PIK3CAAKT1MTORNTRK1PIK3CG | |
| SCHEMBL4755130 | 0.80 | PIK3CA (0.67) | PIK3CAAKT1MTORNTRK1PIK3CG | |
| SCHEMBL731607 | 0.80 | PIK3CA (0.62) | PIK3CAAKT1MTORCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2014-10-02 | — | — | US | claimed |
| US-8404837-B2 | Quinoline derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-03-26 | — | — | US | claimed |
| EP-2596793-B1 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2596793-B1 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2014-10-02 | — | — | US | disclosed |
| US-8785433-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785433-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785433-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140100234-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2192902-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | PIK3CA 13/4885AKT1 95/4885MTOR 154/4885 |
| US-20140100234-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885AKT1 66/4885MTOR 59/4885 |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885AKT1 66/4885MTOR 59/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885AKT1 66/4885MTOR 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.